Elutia secures up to $26M funding, reports Q2 net loss $7.6M; NXT-41x on track

ELUTIA INC.

Secured up to $26M: $15M Avenue Capital credit facility and up to $11M from SimpliDerm divestiture; no equity offering.
Q2 net sales $2.4M (down from $2.7M); net loss $7.6M vs $9.6M; adjusted EBITDA loss $4.6M vs $3.0M.
Surgeon survey: 86% say current matrices increase infection risk; 96% interested in NXT-41x; 92% would champion at hospital.
NXT-41 FDA clearance expected 4Q 2026; NXT-41x 1H 2027; commercial launch 2028.
Cash $19.9M; expects up to $34M additional from signed transactions including $8M BioEnvelope escrow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.